Waddill William D. 4

What Happened

• William D. Waddill, a director of Protagonist Therapeutics (PTGX), exercised vested stock options and sold shares on June 10, 2026. He exercised options to acquire 9,000 shares by paying aggregate exercise prices of $35,400 (3,000 shares at $11.80) and $99,240 (6,000 shares at $16.54) — total cash paid $134,640. On the same day he sold 9,000 shares in the open market for a weighted average price of $107.68, generating proceeds of $969,120.

Key Details

• Transaction date: June 10, 2026.
• Option exercises (M): Acquired 3,000 shares @ $11.80 ( $35,400 ) and 6,000 shares @ $16.54 ( $99,240 ).
• Open-market sale (S): Disposed 9,000 shares at a weighted average price of $107.68; total proceeds $969,120. Reported sale prices ranged from $107.02 to $108.00.
• Additional derivative reporting: Form 4 also shows conversion/disposition entries of 3,000 and 6,000 shares at $0.00 (reporting of option/derivative conversion).
• Shares owned after the transaction: not specified in the provided summary.
• Filing timeliness: Reported the transaction on Form 4 filed June 11, 2026 (timely relative to the June 10 transaction).
• Footnotes: Transactions effected pursuant to a 10b5-1 plan adopted Feb 27, 2026 (F1). Options exercised were fully vested (F3). Weighted average sale price and price range disclosed; breakdown by individual trade available on request (F2).

Context

• This was an exercise of vested options followed by an immediate open-market sale of shares under a pre-established 10b5-1 plan. Such a pattern (exercise then sale) is commonly used to cover option exercise costs and tax obligations; the 10b5-1 plan indicates sales were pre-authorized and scheduled. The filing is factual and does not speak to Waddill’s future views on the company.